Ori Yellin

1.1k total citations
34 papers, 733 citations indexed

About

Ori Yellin is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Ori Yellin has authored 34 papers receiving a total of 733 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 19 papers in Molecular Biology and 18 papers in Oncology. Recurrent topics in Ori Yellin's work include Multiple Myeloma Research and Treatments (27 papers), Protein Degradation and Inhibitors (13 papers) and Bone health and treatments (7 papers). Ori Yellin is often cited by papers focused on Multiple Myeloma Research and Treatments (27 papers), Protein Degradation and Inhibitors (13 papers) and Bone health and treatments (7 papers). Ori Yellin collaborates with scholars based in United States and France. Ori Yellin's co-authors include James R. Berenson, Regina A. Swift, Youram Nassir, Ralph V. Boccia, Robert Vescio, Gabriel N. Waterman, Eric Sanchez, Cathy S. Wang, Haiming Chen and Cydney Nichols and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Ori Yellin

33 papers receiving 721 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ori Yellin United States 14 434 382 365 114 68 34 733
Edit Porpaczy Austria 15 105 0.2× 218 0.6× 160 0.4× 176 1.5× 88 1.3× 27 614
Paul Cheng United States 7 206 0.5× 402 1.1× 117 0.3× 41 0.4× 38 0.6× 11 486
Abdulkadyrov Km Russia 11 776 1.8× 417 1.1× 391 1.1× 33 0.3× 83 1.2× 87 996
Robert F. Cornell United States 21 892 2.1× 598 1.6× 726 2.0× 70 0.6× 63 0.9× 80 1.3k
Nishant Tageja United States 15 212 0.5× 163 0.4× 188 0.5× 15 0.1× 46 0.7× 33 516
Huiying Qiu China 17 817 1.9× 205 0.5× 300 0.8× 9 0.1× 176 2.6× 172 1.2k
Brigitte Puig France 8 112 0.3× 222 0.6× 165 0.5× 34 0.3× 28 0.4× 11 527
RM Stone United States 9 570 1.3× 215 0.6× 282 0.8× 10 0.1× 61 0.9× 13 940
H. Goldschmidt Germany 11 265 0.6× 228 0.6× 147 0.4× 18 0.2× 27 0.4× 34 447
Pamela Bartels United States 7 454 1.0× 198 0.5× 194 0.5× 17 0.1× 199 2.9× 10 740

Countries citing papers authored by Ori Yellin

Since Specialization
Citations

This map shows the geographic impact of Ori Yellin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ori Yellin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ori Yellin more than expected).

Fields of papers citing papers by Ori Yellin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ori Yellin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ori Yellin. The network helps show where Ori Yellin may publish in the future.

Co-authorship network of co-authors of Ori Yellin

This figure shows the co-authorship network connecting the top 25 collaborators of Ori Yellin. A scholar is included among the top collaborators of Ori Yellin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ori Yellin. Ori Yellin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Berenson, James R., James Hilger, Ori Yellin, et al.. (2014). Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. Leukemia. 28(7). 1529–1536. 55 indexed citations
3.
Berenson, James R., Ori Yellin, Chien-Shing Chen, et al.. (2014). A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. Supportive Care in Cancer. 23(6). 1503–1512. 27 indexed citations
4.
5.
Berenson, James R., James Hilger, Ori Yellin, et al.. (2013). A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Annals of Hematology. 93(1). 89–98. 34 indexed citations
6.
Yellin, Ori, Chen‐Li Cheng, Alan Cartmell, et al.. (2012). A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. Leukemia. 26(7). 1675–1680. 32 indexed citations
7.
Berenson, James R., Ori Yellin, Alberto Bessudo, et al.. (2012). Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. British Journal of Haematology. 160(3). 321–330. 39 indexed citations
8.
Waterman, Gabriel N., et al.. (2011). Metatarsal Stress Fractures in Patients with Multiple Myeloma Treated with Long-Term Bisphosphonates. Journal of Bone and Joint Surgery. 93(18). e106–e106. 11 indexed citations
9.
10.
Berenson, James R., Ori Yellin, Ravi Patel, et al.. (2011). A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. British Journal of Haematology. 155(5). 580–587. 25 indexed citations
11.
Berenson, James R., et al.. (2010). A Multicenter Randomized Clinical Trial Comparing a Powered Bone Marrow Biopsy System and Manual Bone Marrow Biopsy Procedures.. Blood. 116(21). 3840–3840. 1 indexed citations
12.
13.
Berenson, James R., Ori Yellin, Alberto Bessudo, et al.. (2010). An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma. Blood. 116(21). 3057–3057.
14.
15.
Berenson, James R. & Ori Yellin. (2009). Monoclonal Gammopathy of Undetermined Significance: Why Identification of These Patients and Assessment of Their Skeletons Is Important. Clinical Lymphoma & Myeloma. 9(4). 311–315. 8 indexed citations
16.
Berenson, James R., Ori Yellin, Ravi Patel, et al.. (2009). A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma. Clinical Cancer Research. 15(3). 1069–1075. 29 indexed citations
17.
Berenson, James R., Ori Yellin, Ravi Patel, et al.. (2009). A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Previously Untreated Multiple Myeloma (MM).. Blood. 114(22). 4936–4936. 1 indexed citations
18.
Berenson, James R., et al.. (2009). A phase II study of a 1-hour infusion of romidepsin combined with bortezomib for multiple myeloma (MM) patients with relapsed or refractory disease. Journal of Clinical Oncology. 27(15_suppl). e19508–e19508. 7 indexed citations
19.
Berenson, James R. & Ori Yellin. (2008). New drugs in multiple myeloma. Current Opinion in Supportive and Palliative Care. 2(3). 204–210. 9 indexed citations
20.
Berenson, James R., Ori Yellin, Donald Woytowitz, et al.. (2007). Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-Tolerated Frontline Regimen.. Blood. 110(11). 3602–3602. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edit Porpaczy Breakdown of academic impact, for papers by Paul Cheng Breakdown of academic impact, for papers by Abdulkadyrov Km Breakdown of academic impact, for papers by Robert F. Cornell Breakdown of academic impact, for papers by Nishant Tageja Breakdown of academic impact, for papers by Huiying Qiu Breakdown of academic impact, for papers by Brigitte Puig Breakdown of academic impact, for papers by RM Stone Breakdown of academic impact, for papers by H. Goldschmidt Breakdown of academic impact, for papers by Pamela Bartels
Rankless by CCL
2026